Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 131Liver Neoplasms 42Carcinoma, Renal Cell 36Leukemia, Myeloid, Acute 32Neoplasm Metastasis 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Kidney Neoplasms 16Neoplasms 14Prostatic Neoplasms 12Pancreatic Neoplasms 12Recurrence 11Lung Neoplasms 11Colorectal Neoplasms 10Sarcoma 9Melanoma 9Brain Neoplasms 9Myelodysplastic Syndromes 8Glioblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Rectal Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Stomach Neoplasms 4Ovarian Neoplasms 4Liver Diseases 4Gliosarcoma 4

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, medullary × Sorafenib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡